Nachrichten aus der Chemie, Journal Year: 2024, Volume and Issue: 72(12), P. 53 - 55
Published: Dec. 1, 2024
Abstract Wirkstoffe, mit denen Aids behandelt wird, verhindern die Krankheit, wenn sie prophylaktisch geschluckt oder gespritzt werden. Dies könnte Bekämpfung der Epidemie revolutionieren – zumindest, Mittel zuverlässig verfügbar sind und auch so genutzt
Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1418 - 1418
Published: Dec. 16, 2024
mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.
Language: Английский
Citations
3
Immunity, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
0
Science, Journal Year: 2025, Volume and Issue: unknown
Published: May 15, 2025
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01 , induced precursors of VRC01-class at high frequency majority recipients. These precursors, that target CD4 receptor binding site, had undergone somatic hypermutation characteristic VRC01-class. subset isolated monoclonal neutralized wild-type pseudoviruses and was structurally extremely similar VRC01. results further support approaches for design demonstrate atomic-level manipulation cell responses rational design.
Language: Английский
Citations
0
Journal of Biomedical Science, Journal Year: 2024, Volume and Issue: 31(1)
Published: Aug. 21, 2024
Abstract Human immunodeficiency virus type 1 (HIV-1) vaccine immunogens capable of inducing broadly neutralizing antibodies (bNAbs) remain obscure. HIV-1 evades immune responses through enormous diversity and hides its conserved vulnerable epitopes on the envelope glycoprotein (Env) by displaying an extensive immunodominant glycan shield. In elite viremic controllers, glycan-dependent bNAbs targeting Env have been isolated are utilized as design templates. However, immunological tolerance mechanisms limit development these in general population. The well characterized monoclonal variants frequently exhibit levels somatic hypermutation, a long third heavy chain complementary determining region, or short light complementarity some poly-reactivity to autoantigens. This review elaborates obstacles engaging manipulating effective immunogen describes alternative reverse vaccinology approach develop novel category bNAb-epitope-derived non-cognate for design. Graphical
Language: Английский
Citations
0
bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 16, 2024
Abstract Broadly neutralizing antibodies (bnAbs) recognizing a diversity of HIV-1 strains are widely thought to be essential for an vaccine. Extensive knowledge on bnAbs has been gained from studying natural HIV infection by following bnAb evolution in individual people with (PWH). However, it remains increase responses large PWH cohorts assess the feasibility inducing activity vaccination. To allow systematic analysis, we created XbnAb cohort, bnAb-inducer cohort selected screening plasma enrolled Swiss Cohort Study (SHCS) and Zurich Primary Infection (ZPHI). The represents retrospective, biobank-based comprising data 304 who developed during infection. Here, report characteristics its potential vaccine research.
Language: Английский
Citations
0
bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 22, 2024
SUMMARY Rare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions protective immunity. However, rare naive infrequently participate in immune responses. We investigated how germline-targeting vaccine antigen delivery and adjuvant selection affect priming of exceptionally BG18-like HIV broadly neutralizing antibody-precursor (~1 50 million) non-human primates. Only escalating dose (ED) immunization using saponin SMNP elicited detectable germinal centers (GCs). All groups had strong GC responses, but only ED+SMNP bolus+SMNP induced memory >50% animals. One group vaccine-specific responses equivalent ED+SMNP, were rarely detected. Following homologous boosting, more frequent a bolus group, lower somatic hypermutation affinities. This outcome was inversely associated with post-prime antibody titers, suggesting feedback significantly influence precursor cell
Language: Английский
Citations
0
Nachrichten aus der Chemie, Journal Year: 2024, Volume and Issue: 72(12), P. 53 - 55
Published: Dec. 1, 2024
Abstract Wirkstoffe, mit denen Aids behandelt wird, verhindern die Krankheit, wenn sie prophylaktisch geschluckt oder gespritzt werden. Dies könnte Bekämpfung der Epidemie revolutionieren – zumindest, Mittel zuverlässig verfügbar sind und auch so genutzt
Citations
0